CLINICAL UPDATES IN ADVANCEMENTS OF TREATMENT OF TNBC, HR+,HER2+, HER2-LOW, BREAST CANCER: ESMO CONGRESS UPDATES

The aim of this educational curriculum is to present and evaluate latest breakthroughs, therapies, and strategies in Breast Cancer (BC) management that have transformed the approach to this complex and chronic condition. The two self-study modules are designed to offer a thorough understanding of the wide range of treatment modalities available. From conventional methods to cutting-edge innovations, providing insights on BC management optimization, including the use of Antibody Drug Conjugates (ADCs), immunotherapy, Parp-inhibitors and a potential therapeutic algorithm for HER2-low breast cancer.

English

Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globally
Apply the most recent evidence-based recommendations when managing patients with HR+ and BRCAm+ BC, based on specific patient and tumor characteristics
Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of treatment optimization for HR+/HER2- breast cancer

Oncology clinicians and specifically those actively involved in the treatment of breast cancer.

A collaboration between Scientific Seminars International Foundation and AXDEV Global Inc. in Join Providership with RealCME and Academic CME